In 2023, the anti-infective medicine sales in Canada were valued at approximately 1.66 billion US dollars, measured in purchasing power parity (PPP). From 2024 to 2028, the market is forecasted to experience a steady, yet modest growth, culminating at 1.7 billion US dollars in PPP by 2028. The year-on-year growth rate over this period is less than 1%, with a compound annual growth rate (CAGR) over five years reflecting a similar trend of about 0.24%. The projected growth suggests a stable but slow-paced market expansion.
Future trends to watch for include potential market drivers such as advancements in biotechnology, increased antibiotic resistance, and the development of new and innovative anti-infective therapies. Additionally, policy changes and a focus on healthcare investment could further influence this market's trajectory.
